Overview: Lipoprotein a TestIntroduction: The Lipoprotein a Test measures Lp(a) to assess heart disease risk, causing chest pain or stroke. Aligned with 2023 AHA guidelines, it uses immunoassay for high specificity, supporting cardiac screening. This test is critical for guiding risk assessment, treatment planning, and improving outcomes in biochemistry for patients with suspected cardiovascular disease.
Other Names: Lp(a) Assay, Cardiac Risk Lipoprotein Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Lp(a) testing began in the 1980s with cardiovascular research. Immunoassay methods improved in the 2000s, enhancing risk assessment precision.
Purpose: Measures Lp(a) to assess heart disease risk, guides treatment, and evaluates patients with chest pain or stroke.
Test Parameters: 1. Lipoprotein (a)
Pretest Condition: Fasting 10-12 hours required. Collect serum or plasma. Report history of chest pain, stroke, or cardiovascular risk factors.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document chest pain, stroke, hypertension, or family history of heart disease. Include current medications, especially statins.
Consent: Written consent required, detailing the tests purpose, cardiac risk implications, and risks of blood collection.
Procedural Considerations: Uses immunoassay to measure Lp(a) in serum or plasma. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for cardiac risk assessment.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Non-fasting samples may reduce accuracy.
Clinical Significance: Elevated Lp(a) indicates high heart disease risk, guiding lipid-lowering therapy or lifestyle changes. Normal levels may require further lipid profiling.
Specialist Consultation: Consult a cardiologist for result interpretation and treatment planning.
Additional Supporting Tests: LDL cholesterol, HDL cholesterol, or coronary artery calcium scan to assess heart disease risk.
Test Limitations: Lp(a) levels are genetically determined; clinical correlation is needed. Not specific to one condition.
References: AHA Lipid Guidelines, 2023; Circulation, Tsimikas S, 2022.
